Literature DB >> 3091857

Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking.

G Oster, D M Huse, T E Delea, G A Colditz.   

Abstract

A nicotine chewing gum has recently become available for use as an aid in giving up cigarette smoking. Although its efficacy has been demonstrated in clinic-based smoking cessation programs, its value in a primary care setting is uncertain. We examined the cost-effectiveness of nicotine gum as an adjunct to physician's advice and counseling against smoking during routine office visits. Our findings indicate that the cost per year of life saved with this intervention ranges from $4113 to $6465 for men and from $6880 to $9473 for women, depending on age. This compares favorably with other widely accepted medical practices, eg, treatment of hypertension or hyperlipidemia. Our study, therefore, suggests that nicotine gum is a cost-effective adjunct to physician's advice against cigarette smoking in a primary care setting.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091857

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  34 in total

1.  Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority.

Authors:  S Parrott; C Godfrey; M Raw; R West; A McNeill
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 2.  The limited incorporation of economic analyses in clinical practice guidelines.

Authors:  Joel F Wallace; Scott R Weingarten; Chiun-Fang Chiou; James M Henning; Andriana A Hohlbauch; Margaret S Richards; Nicole S Herzog; Lior S Lewensztain; Joshua J Ofman
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

3.  The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles.

Authors:  A R Gilbert; C Pinget; P Bovet; J Cornuz; C Shamlaye; F Paccaud
Journal:  Tob Control       Date:  2004-06       Impact factor: 7.552

4.  Long-term impact of smoking cessation on the incidence of coronary heart disease.

Authors:  A N Tosteson; M C Weinstein; L W Williams; L Goldman
Journal:  Am J Public Health       Date:  1990-12       Impact factor: 9.308

Review 5.  The physician's role in injury prevention: beyond the U.S. Preventive Services Task Force report.

Authors:  G S Smith
Journal:  J Gen Intern Med       Date:  1990 Sep-Oct       Impact factor: 5.128

6.  The cost effectiveness of drug utilisation review in an outpatient setting.

Authors:  D H Kreling; D A Mott
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

Review 7.  Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature.

Authors:  D Thompson; G Oster
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

8.  Cost effectiveness of beractant in the prevention of respiratory distress syndrome.

Authors:  R F Soll; J Jacobs; S Pashko; R Thomas
Journal:  Pharmacoeconomics       Date:  1993-10       Impact factor: 4.981

Review 9.  Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage.

Authors:  K E Warner
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

10.  Free nicotine replacement therapy programs vs implementing smoke-free workplaces: a cost-effectiveness comparison.

Authors:  Michael K Ong; Stanton A Glantz
Journal:  Am J Public Health       Date:  2005-06       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.